Ensysce Biosciences
ENSC
8 hedge funds and large institutions have $1.15M invested in Ensysce Biosciences in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 8 closing their positions.
97% more capital invested
Capital invested by funds: $581K → $1.15M (+$565K)
9.32% more ownership
Funds ownership: 1.43% → 10.75% (+9.3%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
33% less funds holding
Funds holding: 12 → 8 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$597K |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$345K |
| 3 |
FIA
FNY Investment Advisers
New York
|
+$20.7K |
| 4 |
Morgan Stanley
New York
|
+$358 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$55 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$279K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$236K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$47.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$11.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.67K |
ENSC Hedge Fund Activity: Q4 2024 in Review
8 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q4 2024, worth a combined $1.15M — up 97% from $581K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ENSC and 4 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $597K. The largest seller was Sabby Management, exiting entirely with an estimated $279K sold.
- 8 institutional investors held Ensysce Biosciences (ENSC) as of Q4 2024, down from 12 in Q3 2024.
- Funds reported $1.15M of Ensysce Biosciences stock for Q4 2024, up 97% quarter-over-quarter.
- 4 funds opened new Ensysce Biosciences positions in Q4 2024 and 8 closed out, a net change of -4 holders.
- The largest Ensysce Biosciences buyer in Q4 2024 was Perceptive Advisors, an estimated $597K added.
- The largest Ensysce Biosciences seller in Q4 2024 was Sabby Management, an estimated $279K sold.
Based on aggregated 13F filings for Q4 2024.